Back to News
Market Impact: 0.6

CME Group stock a ‘Buy', analysts see ‘numerous catalysts ahead‘

CMEC
Analyst InsightsCompany FundamentalsCorporate Guidance & OutlookCapital Returns (Dividends / Buybacks)Analyst EstimatesInterest Rates & YieldsEnergy Markets & PricesFutures & Options
CME Group stock a ‘Buy', analysts see ‘numerous catalysts ahead‘

Citi analysts upgraded CME Group (NASDAQ:CME) to 'Buy' from 'Hold', setting a US$300 price target and implying an 18% total return, citing an attractive risk/reward profile. The upgrade is predicated on numerous upcoming catalysts, including UST clearing and OSSTRA, a robust capital return outlook with an estimated $3.3 billion to $3.6 billion in shareholder returns, and the platform's defensive characteristics, despite recent headwinds from lower trading volumes.

Analysis

Citi analysts have upgraded CME Group (CME) to 'Buy' from 'Hold', setting a US$300 price target that implies an 18% total return. The basis for the upgrade is a positive risk/reward profile at current levels, supported by several anticipated catalysts in the coming months, including UST clearing, OSSTRA, and a Fanduel partnership. The analysts' note highlights a robust capital return outlook, with an estimated $3.3 billion to $3.6 billion to be returned to shareholders through buybacks and dividends, funded by cash on hand, future generation, and OSSTRA proceeds. While acknowledging near-term headwinds from lower trading volumes due to reduced interest rate and energy volatility, Citi's research frames this as a strategic opportunity, noting that historically, stock weakness on low volumes has presented favorable entry points for acquiring CME shares.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo